IXHL has been on my radar since the US listing, however 12 months ago the company had limited clinical data and a valuation that exceeded some of the highly regarded biotech names on NASDAQ.
The investment proposition is substantially better now with a year of positive data and a valuation that’s a fraction of its 12 month highs.
Not only does it stack up, it’s possibly the best leveraged investment in the sector on any exchange from my perspective.Whatever the catalyst has been for the recent sell off, it’s created an outstanding opportunity to build a position.
IHL Price at posting:
11.0¢ Sentiment: Buy Disclosure: Held
